IGFL2-AS1 (IGFL2 Antisense RNA 1)

Notably, overexpression of IGFL2-AS1 in HeLa cells significantly reduced cell proliferation, migration, clonogenic survival, and enhanced sensitivity to cisplatin and doxorubicin. Conversely, IGFL2-AS1 repression in SiHa cells yielded no significant phenotypic changes, suggesting a context-dependent mechanism. IGFL2-AS1 is identified as a histological subtype-specific prognostic biomarker and promising therapeutic target for cervical adenocarcinoma.

This study demonstrated that the YBX1-modulated IGFL2-AS1/HSPA1A/RAP1 axis is aberrantly activated in lung cancer cells and is associated with unfavorable prognosis, highlighting its potential as a novel therapeutic target in clinical settings.

Additional subgroup analysis showed that PSMB8-AS1 is an unfavorable prognostic factor for squamous cell lung cancer (hazard ratio (HR)= 4.482, p = 0.027). Further investigation of non-coding RNAs in NSCLC is promising for identifying new markers for the diagnosis and prognosis of this disease.

The prognostic model effectively predicts HNSCC outcomes, with better prognosis in the low-risk group. DSTN upregulation promotes tumor growth, and its knockout inhibits proliferation, migration, and invasion.

We found that knocking down LINC02154 and AC112715.1 could inhibit the invasion ability of renal cancer cells. The risk model based on BM-associated lncRNAs can well predict ccRCC and guide clinical treatment.

In vivo xenografted mouse model also elucidated that inhibition of AR activity with enzalutamide or silence of IGFL2-AS1 with siRNAs all led to retarded growth of pazopanib resistant ccRCC tumors. Together, these results suggest that IGFL2-AS1 may represent a key player to mediate pazopanib-induced VM formation of ccRCC cells via regulating AR expression and targeting this newly identified IGFL2-AS1/AR signaling may help us to better suppress ccRCC VM formation and to increase the therapeutic efficacy of pazopanib.

Immunity analysis proclaimed a striking difference in terms of cells, function, checkpoints, and ESTIMATE scores between low- and high-risk groups. Overall, the innovative signature of ferroptosis-associated signatures may have a considerable effect on the immune response and prognosis for ccRCC.

We also showed that downstream effectors of the AKT pathway played crucial roles. These data suggest that IGFL2-AS1 contributes to the acquisition of radioresistance by regulating the AKT pathway.

LncRNA IGFL2-AS1 was abundantly expressed in colorectal cancer tissues and cells, and comparatively bound to miR433-3p to facilitate PAK4 transcription, thus promoting HCT116 cell malignant proliferation.

Our findings suggested that IGFL2-AS1 is expected to be a promising new diagnostic marker and therapeutic target for CRC.